Crinetics Pharmaceuticals Reports Strong Q4 and Full Year 2025 Results

Approval and Launch of PALSONIFY Drives Robust Revenue Growth

Apr. 16, 2026 at 2:26pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of shiny metal cubes, a glass beaker, and a polished metal sphere arranged elegantly on a clean, monochromatic seamless background, conceptually representing Crinetics' corporate strategy and financial performance.Crinetics' strong financial results and pipeline progress signal the company's continued momentum in the endocrinology space.San Diego Today

Crinetics Pharmaceuticals, a global pharmaceutical company focused on endocrine diseases, reported strong financial results for the fourth quarter and full year 2025. The company's lead product, PALSONIFY, received FDA approval in September 2025 and generated $5.4 million in net product revenue during its Q4 2025 launch. Crinetics also advanced its pipeline, including initiating three pivotal trials for paltusotine and atumelnant.

Why it matters

Crinetics' successful launch of PALSONIFY, its first approved product, demonstrates the company's ability to bring innovative therapies to market and build a commercial business. The strength of Crinetics' pipeline and financial position also positions the company to continue defining the future of endocrinology treatments.

The details

Crinetics reported $6.2 million in revenue for Q4 2025 and $7.7 million for the full year, driven by $5.4 million in PALSONIFY net product sales. The company also initiated three pivotal trials, including for paltusotine in carcinoid syndrome and atumelnant in congenital adrenal hyperplasia and Cushing's syndrome. Crinetics ended 2025 with $1 billion in cash and cash equivalents.

  • PALSONIFY received FDA approval on September 25, 2025.
  • Crinetics initiated three pivotal trials in 2025, including the CAREFNDR Phase 3 trial for paltusotine in carcinoid syndrome, the CALM-CAH Phase 3 trial for atumelnant in congenital adrenal hyperplasia, and the BALANCE-CAH Phase 2/3 trial for atumelnant in pediatric congenital adrenal hyperplasia.
  • Crinetics finalized the protocol for the pivotal Phase 2/3 EQUILIBRIUM study of atumelnant in ACTH-dependent Cushing's Syndrome, with the first patient expected to enroll in the first half of 2026.

The players

Crinetics Pharmaceuticals, Inc.

A global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors.

Scott Struthers, Ph.D.

Founder and chief executive officer of Crinetics Pharmaceuticals.

PALSONIFY (paltusotine)

Crinetics' lead product, the first and only once-daily oral somatostatin receptor ligand approved by the FDA for the treatment of acromegaly.

Atumelnant

Crinetics' late-stage investigational candidate currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.

CRN09682

Crinetics' first candidate from its proprietary nonpeptide drug conjugate (NDC) platform, being developed to treat SST2 expressing neuroendocrine tumors and other solid tumors.

Got photos? Submit your photos here. ›

What they’re saying

“2025 was a breakout year for Crinetics, as the approval and launch of Palsonify demonstrated our ability to bring an innovative therapy from concept to the patients who need it most.”

— Scott Struthers, Ph.D., Founder and chief executive officer of Crinetics Pharmaceuticals

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Crinetics' successful launch of its first approved product, PALSONIFY, and the strength of its pipeline and financial position position the company to continue defining the future of endocrinology treatments.